Annexon, Inc.
corporate_fare Company Profile
Annexon, Inc. (NASDAQ:ANNX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for ANNX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for ANNX spans 8-K, 10-Q, 4, PRE 14A.
Recent high-impact activity:
- Annexon Posts Q3 Loss of $0.25/Share, $213M Cash, Adds $200M Oxford Credit Facility
- Annexon Posts $51.2M Q3 Loss, Adds $200M Oxford Credit Facility Ahead of Q4 BLA Filing
- Annexon Q2 2026: $55.3M Net Loss, Cash Runway Extended into 2028
- Annexon Posts Q2 Loss of $0.28/Share, Expands Phase 3 GA Trial with Dual Endpoint, and Sets Key Milestones
- Annexon Posts 28c Q2 Loss, Cash Runway in Focus
Financial Snapshot
Short Interest & Short Volume
7.19 days to coverFINRA reported short interest of 28,984,850 shares in ANNX as of the October 30, 2026 settlement, a 8.4% decrease from the prior period — about 7.2 days to cover at its recent average daily volume. On November 20, 2026, 36.5% of ANNX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for ANNX, detected from its recent SEC filings · based on capital-structure filings through 2026-06-12.
Authorized Shares Increased · Significant Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →